ALT - Latest News
Altimmune, Inc. (ALT), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $571.8M. Beta to the broader market is 0.17.
The article list below shows the most recent ALT headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ALT Headlines
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus
zacks.com - Aug 13, 2026
Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.
Dimensional Fund Advisors LP Raises Stake in Altimmune, Inc. $ALT
defenseworld.net - Aug 13, 2026
Dimensional Fund Advisors LP raised its holdings in Altimmune, Inc. (NASDAQ: ALT) by 268.
Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript
seekingalpha.com - Aug 12, 2026
Altimmune, Inc.
Altimmune Q2 Earnings Call Highlights
marketbeat.com - Aug 12, 2026
Altimmune NASDAQ: ALT said it has initiated patient enrollment in its global Phase III PERFORMA trial of pemvidutide for metabolic dysfunction-associa
Altimmune Announces Second Quarter 2026 Financial Results and Business Update
globenewswire.com - Aug 12, 2026
Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTO
How News Affects ALT Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ALT's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ALT news questions
- What is the latest ALT news headline?
- The most recent ALT headline (Aug 13, 2026) is "ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ALT news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ALT news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ALT options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.